The presence of tumor‐specific CD8+TRM‐like cells (CD39+CD8+T) has been associated with better overall survival in several solid tumors [24, 26, 142, 143], reinforcing the notion that targeting these specific immune populations could be a promising strategy for enhancing cancer immunotherapy. This evidence concerns the gene CD8A and cancer.